In hepatocellular and lung adenocarcinoma, no association of the CTNNB1 mutational status with prognosis was found, while in certain subtypes of early stage endometrial carcinoma, CTNNB1 mutations predicted disease recurrence and reduced disease-free survival [111,112,113]. This evidence concerns the gene CTNNB1 and lung adenocarcinoma.